[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100653887":3},{"organization":4,"outcomesModule":7,"designInfo":27,"detailedDescription":30,"studyPopulation":30,"armGroups":34,"interventions":41,"overallOfficials":30,"centralContacts":45,"locations":55,"responsibleParty":71,"collaborators":30,"id":74,"slug":75,"hasResults":76,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":30,"eligibilityCriteria":80,"healthyVolunteers":76,"sex":81,"minAge":82,"maxAge":30,"enrollmentInfo":83,"targetDuration":30,"studyType":86,"phases":87,"briefSummary":88,"conditions":89,"keywords":94,"overallStatus":99,"whyStopped":30,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},{"fullName":5,"class":6},"Zhejiang University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":23},[9],{"measure":10,"description":11,"timeFrame":12},"The incidence of hypoxemia","75% ≤ SpO2 \\\u003C 90% for \\\u003C60 s","Patients will be followed for the duration of hospital stay, an expected average about 2 hours",[14,17,20],{"measure":15,"description":16,"timeFrame":12},"The incidence of sub-clinical respiratory depression","90% ≤ SpO2 \\\u003C 95%",{"measure":18,"description":19,"timeFrame":12},"The incidence of severe hypoxemia","SpO2 \\\u003C 75% or 75% ≤ SpO2 \\\u003C 90% for ≥60 s",{"measure":21,"description":22,"timeFrame":12},"The incidence of other adverse events","Other adverse events recorded by tools proposed by the World Society of Intravenous Anesthesia International Sedation Task Force",[24],{"measure":25,"description":26,"timeFrame":12},"QoR-PACU₂-15 score at PACU discharge","QoR-PACU₂-15 assessed at PACU discharge to evaluate early recovery quality (15 items, each scored 0-5; total score 0-75, higher scores indicate better recovery).",{"allocation":28,"interventionModel":29,"interventionModelDescription":30,"primaryPurpose":31,"observationalModel":30,"timePerspective":30,"maskingInfo":32},"NA","SINGLE_GROUP",null,"PREVENTION",{"masking":33,"maskingDescription":30,"whoMasked":30},"NONE",[35],{"label":36,"type":37,"description":38,"interventionNames":39},"High-flow nasal cannula","EXPERIMENTAL","Using high-flow nasal cannula oxygenation",[40],"Device: High-flow nasal cannula",[42],{"type":43,"name":36,"description":38,"armGroupLabels":44,"otherNames":30},"DEVICE",[36],[46,51],{"name":47,"role":48,"phone":49,"phoneExt":30,"email":50},"Diansan Su","CONTACT","+8618616514088","diansansu@yahoo.com",{"name":52,"role":48,"phone":53,"phoneExt":30,"email":54},"Mingxia Xu","+8613516713435","xumingxia@zju.edu.cn",[56],{"facility":57,"status":30,"city":58,"state":59,"zip":60,"country":61,"countryCode":62,"cosmosGeoPoint":63,"geoPoint":68,"contacts":69},"The First Affiliated Hospital, Zhejiang University School of Medicine","Hangzhou","Zhejiang","310000","China","CN",{"type":64,"coordinates":65},"Point",[66,67],120.16142,30.29365,{"lat":67,"lon":66},[70],{"name":47,"role":48,"phone":49,"phoneExt":30,"email":50},{"type":72,"investigatorFullName":47,"investigatorTitle":73,"investigatorAffiliation":5,"oldNameTitle":30,"oldOrganization":30},"PRINCIPAL_INVESTIGATOR","Chief Physician,Researcher","100653887","high-flow-nasal-cannula-oxygenation-during-sedated-gastrointestinal-endoscopy-in-patients-with-chronic-obstructive-pulmonary-disease-100653887",false,"NCT07791979","High-Flow Nasal Cannula Oxygenation During Sedated Gastrointestinal Endoscopy in Patients With Chronic Obstructive Pulmonary Disease","High-Flow Nasal Cannula Oxygenation During Sedated Gastrointestinal Endoscopy in Patients With Chronic Obstructive Pulmonary Disease: A Single-Arm Simon Two-Stage Study","Inclusion Criteria:\n\n* Age ≥18 years;\n* Confirmed diagnosis of chronic obstructive pulmonary disease (COPD);\n* Scheduled for elective sedated gastroenteroscopy (gastroscopy, colonoscopy, or combined gastroscopy and colonoscopy);\n* Expected procedure duration ≤45 minutes;\n* Provision of written informed consent by the participant.\n\nExclusion Criteria:\n\n* Patients with absolute contraindications to high-flow therapy, including but not limited to confirmed diagnosis of complete upper airway obstruction, basilar skull fracture or nasal bone fracture, pneumothorax, or pneumomediastinum.;\n* American Society of Anesthesiologists (ASA) Physical Status class ≥ IV;\n* Requirement for planned endotracheal intubation;\n* Existing tracheostomy;\n* Confirmed pregnancy or currently breastfeeding;\n* Known allergy to sedative agents such as propofol;\n* Current participation in another interventional clinical trial;\n* Any other condition deemed by the investigator to make the patient unsuitable for trial participation.","ALL","18 Years",{"count":84,"type":85},90,"ESTIMATED","INTERVENTIONAL",[28],"Hypoxemia is the most common adverse event during propofol sedation for gastrointestinal endoscopy in patients with chronic obstructive pulmonary disease (COPD) due to diminished pulmonary reserve. Although high-flow nasal cannula (HFNC) oxygenation has been shown to effectively reduce hypoxemia during sedated endoscopy in obese patients, its application in COPD patients remains an evidence gap, largely owing to the traditional concern that high-concentration oxygen may suppress respiratory drive and exacerbate CO₂ retention. This study aims to investigate whether HFNC can reduce the incidence of hypoxemia during sedated gastrointestinal endoscopy in patients with COPD.",[90,91,92,93],"Hypoxemia","Gastric Cancer (Diagnosis)","Chronic Obstructive Pulmonary Disease (COPD)","Esophageal Cancer",[95,90,96,97,98],"high-flow nasal cannula","Chronic Obstructive Pulmonary Disease","Sedation","Gastrointestinal Endoscopy","NOT_YET_RECRUITING","2026-08-26",{"date":102,"type":103},"2026-08-28","ACTUAL",{"date":105,"type":85},"2026-08-29",{"date":107,"type":85},"2027-02-23",{"name":5,"class":6},1]